Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.

Michelle A. Elliott, Ayalew Tefferi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Patients with essential thrombocythemia (ET) and polycythemia vera (PV) have a paradoxical predisposition to bleeding and thrombotic complications that are major causes of morbidity and mortality. Bleeding manifestations are often associated with extreme thrombocytosis that may lead to acquired von Willebrand syndrome (AVWS). Symptomatic AVWS, in this instance, is managed by platelet cytoreductive therapy and, in case of a life-threatening situation, platelet apheresis may be of additional value. Qualitative platelet defects are prevalent in PV and ET but have not been consistently linked to clinical bleeding. However, in vitro and in vivo hemostatic defects in these disorders are either precipitated or exacerbated by the use of aspirin or other nonsteroidal anti-inflammatory drugs. Additional patient management issues are raised during systemic anticoagulation and surgery. This review summarizes putative pathogenetic mechanisms of bleeding and their management in ET and PV.

Original languageEnglish (US)
Pages (from-to)344-351
Number of pages8
JournalCurrent hematology reports.
Volume3
Issue number5
StatePublished - Sep 2004

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Hemorrhage
Blood Platelets
Thrombocytosis
Blood Component Removal
Hemostatics
Aspirin
Anti-Inflammatory Agents
Morbidity
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera. / Elliott, Michelle A.; Tefferi, Ayalew.

In: Current hematology reports., Vol. 3, No. 5, 09.2004, p. 344-351.

Research output: Contribution to journalArticle

@article{2420ed505c4d452a92733f35a5dca36e,
title = "Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.",
abstract = "Patients with essential thrombocythemia (ET) and polycythemia vera (PV) have a paradoxical predisposition to bleeding and thrombotic complications that are major causes of morbidity and mortality. Bleeding manifestations are often associated with extreme thrombocytosis that may lead to acquired von Willebrand syndrome (AVWS). Symptomatic AVWS, in this instance, is managed by platelet cytoreductive therapy and, in case of a life-threatening situation, platelet apheresis may be of additional value. Qualitative platelet defects are prevalent in PV and ET but have not been consistently linked to clinical bleeding. However, in vitro and in vivo hemostatic defects in these disorders are either precipitated or exacerbated by the use of aspirin or other nonsteroidal anti-inflammatory drugs. Additional patient management issues are raised during systemic anticoagulation and surgery. This review summarizes putative pathogenetic mechanisms of bleeding and their management in ET and PV.",
author = "Elliott, {Michelle A.} and Ayalew Tefferi",
year = "2004",
month = "9",
language = "English (US)",
volume = "3",
pages = "344--351",
journal = "Current hematology reports",
issn = "1540-3408",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.

AU - Elliott, Michelle A.

AU - Tefferi, Ayalew

PY - 2004/9

Y1 - 2004/9

N2 - Patients with essential thrombocythemia (ET) and polycythemia vera (PV) have a paradoxical predisposition to bleeding and thrombotic complications that are major causes of morbidity and mortality. Bleeding manifestations are often associated with extreme thrombocytosis that may lead to acquired von Willebrand syndrome (AVWS). Symptomatic AVWS, in this instance, is managed by platelet cytoreductive therapy and, in case of a life-threatening situation, platelet apheresis may be of additional value. Qualitative platelet defects are prevalent in PV and ET but have not been consistently linked to clinical bleeding. However, in vitro and in vivo hemostatic defects in these disorders are either precipitated or exacerbated by the use of aspirin or other nonsteroidal anti-inflammatory drugs. Additional patient management issues are raised during systemic anticoagulation and surgery. This review summarizes putative pathogenetic mechanisms of bleeding and their management in ET and PV.

AB - Patients with essential thrombocythemia (ET) and polycythemia vera (PV) have a paradoxical predisposition to bleeding and thrombotic complications that are major causes of morbidity and mortality. Bleeding manifestations are often associated with extreme thrombocytosis that may lead to acquired von Willebrand syndrome (AVWS). Symptomatic AVWS, in this instance, is managed by platelet cytoreductive therapy and, in case of a life-threatening situation, platelet apheresis may be of additional value. Qualitative platelet defects are prevalent in PV and ET but have not been consistently linked to clinical bleeding. However, in vitro and in vivo hemostatic defects in these disorders are either precipitated or exacerbated by the use of aspirin or other nonsteroidal anti-inflammatory drugs. Additional patient management issues are raised during systemic anticoagulation and surgery. This review summarizes putative pathogenetic mechanisms of bleeding and their management in ET and PV.

UR - http://www.scopus.com/inward/record.url?scp=33745523848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745523848&partnerID=8YFLogxK

M3 - Article

C2 - 15341701

AN - SCOPUS:33745523848

VL - 3

SP - 344

EP - 351

JO - Current hematology reports

JF - Current hematology reports

SN - 1540-3408

IS - 5

ER -